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Background
Surgical ventricular reconstruction is a specific procedure designed to reduce left 
ventricular volume in patients with heart failure caused by coronary artery disease. 
We conducted a trial to address the question of whether surgical ventricular recon-
struction added to coronary-artery bypass grafting (CABG) would decrease the rate 
of death or hospitalization for cardiac causes, as compared with CABG alone.
Methods
Between September 2002 and January 2006, a total of 1000 patients with an ejection 
fraction of 35% or less, coronary artery disease that was amenable to CABG, and 
dominant anterior left ventricular dysfunction that was amenable to surgical ven-
tricular reconstruction were randomly assigned to undergo either CABG alone (499 
patients) or CABG with surgical ventricular reconstruction (501 patients). The pri-
mary outcome was a composite of death from any cause and hospitalization for 
cardiac causes. The median follow-up was 48 months.
Results
Surgical ventricular reconstruction reduced the end-systolic volume index by 19%, 
as compared with a reduction of 6% with CABG alone. Cardiac symptoms and ex-
ercise tolerance improved from baseline to a similar degree in the two study groups. 
However, no significant difference was observed in the primary outcome, which 
occurred in 292 patients (59%) who were assigned to undergo CABG alone and in 
289 patients (58%) who were assigned to undergo CABG with surgical ventricular 
reconstruction (hazard ratio for the combined approach, 0.99; 95% confidence in-
terval, 0.84 to 1.17; P = 0.90).
Conclusions
Adding surgical ventricular reconstruction to CABG reduced the left ventricular 
volume, as compared with CABG alone. However, this anatomical change was not 
associated with a greater improvement in symptoms or exercise tolerance or with a 
reduction in the rate of death or hospitalization for cardiac causes. (ClinicalTrials.
gov number, NCT00023595.)
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Coronary artery disease is the pre-dominant cause of heart failure, which is a major cause of death and disability through-
out the world. Evidence-based medical therapy has 
been shown to reduce symptoms and increase sur-
vival in patients with heart failure and coronary 
artery disease.1 In addition, selected patients may 
benefit from surgical revascularization by means 
of coronary-artery bypass grafting (CABG), espe-
cially if the coronary anatomy is suitable for such 
surgery and if there is evidence of myocardial vi-
ability.2,3
The reduction in left ventricular function that 
can occur after myocardial infarction is typically 
accompanied by left ventricular remodeling, a pro-
cess that includes left ventricular enlargement and 
changes in chamber geometry. Left ventricular 
remodeling is correlated with progression of heart 
failure and a poor prognosis,4,5 and the benefi-
cial effects of therapeutic agents such as angio-
tensin-converting–enzyme (ACE) inhibitors and 
beta-blockers are associated with their effect on 
remodeling.4,6-9 These findings have generated 
considerable interest in the possibility that a sur-
gical approach to remodeling through left ven-
tricular volume reduction could improve outcomes 
for patients with coronary artery disease and heart 
failure.10
Surgical ventricular reconstruction is a specific 
surgical procedure developed for the management 
of heart failure with left ventricular remodeling 
caused by coronary artery disease.11 This opera-
tion has been shown to reduce the left ventricu-
lar volume, increase the ejection fraction, and im-
prove ventricular function.12,13 On the basis of a 
small, nonrandomized, case–control study,14 it has 
been suggested that surgical ventricular recon-
struction that is performed together with CABG 
may reduce the rate of hospitalization and im-
prove ventricular function to a greater degree than 
CABG alone.
The Surgical Treatment for Ischemic Heart Fail-
ure (STICH) trial was designed to define the role 
of cardiac surgery in the treatment of patients with 
heart failure and coronary artery disease.15,16 One 
of the two major hypotheses of this trial (Hypoth-
esis 2) was that surgical ventricular reconstruction, 
when added to CABG, would decrease the rate of 
death or hospitalization for a cardiac event, as com-
pared with CABG alone.
Me thods
Study Design
We conducted a multicenter, nonblinded, random-
ized trial at 127 clinical sites in 26 countries.15 The 
trial was sponsored by the National Heart, Lung, 
and Blood Institute (NHLBI) of the National In-
stitutes of Health. Additional support was provided 
by Abbott Laboratories, Chase Medical, and CV 
Therapeutics, which had no role in the design, con-
duct, or reporting of the trial. The trial protocol 
was designed by the authors in collaboration with 
the NHLBI and was approved by the appropriate 
institutional review board or ethics committee at 
each study center. Trial operations, site manage-
ment and monitoring, and data collection and 
analysis were coordinated by the Duke Clinical 
Research Institute. Oversight was provided by an 
independent data and safety monitoring board. 
A clinical events committee whose members were 
unaware of study-group assignments adjudicated 
primary outcome events. The authors wrote the 
manuscript and vouch for the completeness and 
accuracy of the data and the analyses.
Selection of Patients and Randomization
Patients were eligible for enrollment if they had 
coronary artery disease that was amenable to CABG 
and if they had a left ventricular ejection fraction 
of 35% or less (Fig. 1). Exclusion criteria were a 
recent myocardial infarction, a need for aortic-valve 
replacement, a planned percutaneous coronary in-
tervention (PCI), and coexisting noncardiac dis-
ease resulting in a life expectancy of less than 
3 years. All patients provided written informed 
consent.
After initial determination of overall eligibil-
ity for the trial, patients were evaluated to deter-
mine which component of the STICH program 
was appropriate for them on the basis of suitable 
therapeutic options for that patient (medical ther-
apy alone, CABG alone, or CABG plus surgical 
ventricular reconstruction) (Fig. 1). Patients who 
had stenosis of the left main coronary artery of 
50% or more or who had angina of Canadian Car-
diovascular Society (CCS) class III or IV while re-
ceiving medical therapy were not eligible for 
medical therapy alone. All patients underwent car-
diac imaging for assessment of left ventricular 
function and wall motion. Patients who were 
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found to have dominant anterior akinesia or dys-
kinesia of the left ventricle were considered to have 
disease that was amenable to surgical ventricular 
reconstruction. 
Using these guidelines, physicians who were 
responsible for the conduct of the trial selected 
the randomization stratum for each patient that 
appeared to offer treatment possibilities with 
equivalent potential risks and benefits. Permuted-
block randomization was used, with stratification 
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Figure 1. Enrollment and Outcomes in the STICH Hypothesis 1 and Hypothesis 2 Trials.
Eligible patients who had an ejection fraction of 35% or less and coronary artery disease that was amenable to coronary-artery bypass 
grafting (CABG) were stratified for randomization on the basis of protocol criteria regarding eligibility for medical therapy and for surgi-
cal ventricular reconstruction (SVR). Patients who were eligible for medical therapy with or without CABG but not for CABG with SVR 
were randomly assigned within stratum A. Data from these patients are being collected in the ongoing Hypothesis 1 component of the 
Surgical Treatment of Ischemic Heart Failure (STICH) trial. Patients who were eligible for medical therapy with or without CABG or for 
CABG with SVR were randomly assigned withi  stratum B. Patients who were not eligible for medical therapy alone but who were eligi-
ble for CABG or CABG with SVR were randomly assigned within stratum C. Patients in stratum B and stratum C who were then random-
ly assigned to undergo CABG with or without SVR are included in the 1000-patient cohort that was evaluated in the Hypothesis 2 trial. 
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according to clinical site and according to whether 
the patient was a candidate for SVR, for medical 
therapy alone, or for both (Fig. 1).
The resulting trial included two major compo-
nents. Patients in the Hypothesis 1 component 
were randomly assigned to receive either medi-
cal therapy alone or medical therapy plus CABG. 
The Hypothesis 1 component of the trial is ongo-
ing. Patients in the Hypothesis 2 component were 
randomly assigned to receive either medical ther-
apy plus CABG or medical therapy plus CABG and 
surgical ventricular reconstruction. The results of 
the Hypothesis 2 component are the subject of this 
report.
Treatment
Guideline-based recommendations for drug and 
device use were emphasized for all patients. The 
lead cardiologist at each site was responsible for 
monitoring to ensure that ACE inhibitors, angio-
tensin-receptor blockers, beta-blockers, aldoster-
one antagonists, antiplatelet agents, statins, diuret-
ics, digitalis, pacemakers (for bradyarrhythmias 
or for cardiac resynchronization), and implant-
able cardioverter–defibrillators were used prop-
erly throughout the study.
Cardiac surgeons were individually certified to 
participate in the trial if they met prespecified 
performance criteria. For CABG certification, sur-
geons were required to provide data on at least 
25 patients with a left ventricular ejection fraction 
of 40% or less who underwent CABG, with a death 
rate of 5% or less. Education in the operative tech-
nique for surgical ventricular reconstruction and 
perioperative management was made available be-
fore patient enrollment and during investigator 
meetings. Certification of individual surgeons for 
performing surgical ventricular reconstruction re-
quired evidence of a consistent postoperative de-
crease in left ventricular volume in five consecu-
tive patients who survived the operation.
During CABG, arterial grafting for stenosis of 
the left anterior descending coronary artery was 
required for all patients without specific contrain-
dications. The use of additional arterial conduits 
supplemented by vein grafts was recommended for 
revascularization of all major vessels with clini-
cally significant stenoses. Concurrent mitral-valve 
surgery for regurgitation was performed at the 
discretion of the surgeon.
The technique of surgical ventricular recon-
struction has been described previously.11,12,17 For 
patients who were assigned to undergo surgical 
ventricular reconstruction, this component of the 
operation was most commonly performed dur-
ing a single period of cardioplegic arrest after 
construction of bypass grafts. However, the pro-
cedure could also be performed with the heart 
beating in order to facilitate identification of the 
noncontractile zone of scarring. In this procedure, 
after an anterior left ventriculotomy is centered in 
the zone of anterior asynergy, a suture is placed 
in the interior of the ventricle to encircle the scar 
at the boundary between the akinetic and viable 
tissue. Tightening of this suture brings the healthy 
portions of the ventricular walls together. Visual 
inspection and palpation facilitate the judgment 
of whether a patch is needed to optimize the 
chamber size without deforming the left ventri-
cle during closure of the ventriculotomy.
Primary and Secondary Outcomes
Major perioperative events and specified end points 
were recorded at discharge or at 30 days for pa-
tients remaining in the hospital. Patients were eval-
uated at 4-month intervals after randomization 
during the first year and thereafter at 6-month 
intervals.
Symptoms of angina and heart failure were 
assessed at each follow-up visit. All patients who 
were able to do so performed a 6-minute walk test 
at baseline, at 4 months, and annually thereafter. 
Left ventricular volumes and function were as-
sessed with the use of echocardiography, cardiac 
magnetic resonance imaging, or single photon 
emission computed tomography at baseline, at 
4 months, and at 2 years.
The primary outcome was the time to death 
from any cause or hospitalization for cardiac 
causes. Secondary outcomes included death from 
any cause at 30 days, hospitalization for any cause 
and for cardiovascular causes, myocardial infarc-
tion, and stroke.
Statistical Analysis
We calculated that we would need to enroll 1000 
patients in the trial for a power of 90% to detect a 
20% reduction in the relative risk of death or hos-
pitalization for cardiac causes, assuming a 3-year 
event rate in the CABG-only group of 45% or more 
and allowing for a crossover rate of up to 20%. 
All major study-group comparisons were per-
formed according to the intention-to-treat prin-
ciple. Supplementary analyses tabulated postoper-
ative complications and clinical events occurring 
within 30 days, according to the type of opera-
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tion that was performed. All statistical tests were 
two-tailed. Cumulative event rates from the time 
of randomization were calculated with the use of 
the Kaplan–Meier method.18 The log-rank test for 
time-to-event data was used for the statistical com-
parison of study groups with respect to the pri-
mary outcome and overall mortality.19 Hazard ra-
tios with associated 95% confidence intervals were 
derived with the use of the Cox proportional-
hazards model.20 The Cox model was also used 
to assess the consistency of treatment effects by 
testing for interactions between the type of sur-
gery and prespecified baseline characteristics.
Eight interim analyses of the data were per-
formed and reviewed by the data and safety moni-
toring board. Interim comparisons between study 
groups were monitored with the use of two-sided, 
symmetric O’Brien–Fleming boundaries gener-
ated with the alpha-spending-function approach 
to group-sequential testing.21,22 A P value of 0.05 
or less was considered to indicate statistical sig-
nificance. Because of the sequential monitoring, 
the level of significance that was required for the 
primary analysis at the completion of the study 
was 0.04.
R esult s
Study Population
Between July 24, 2002, and May 5, 2007, 2136 
patients were enrolled in the overall STICH trial 
(Fig. 1). Of these patients, 1000 were enrolled in 
the Hypothesis 2 component at 96 clinical sites 
between September 12, 2002, and January 24, 2006, 
and were randomly assigned to undergo either 
CABG alone (499 patients) or CABG with surgi-
cal ventricular reconstruction (501 patients), with 
follow-up continued through December 31, 2008. 
No significant differences between the two study 
groups were observed in baseline demographic or 
clinical characteristics (Table 1). The median age 
was 62 years, and 147 of the 1000 patients were 
women. The median left ventricular ejection frac-
tion was 28%. The median end-systolic volume 
index was 82 ml per square meter of body-surface 
area. Multivessel coronary artery disease was pres-
ent in 913 patients; 197 patients had stenosis of 
the left main coronary artery.
Surgical Procedures
Of the 499 patients who were assigned to undergo 
CABG alone, 463 (93%) underwent the assigned 
procedure; 9 did not undergo any surgery, and 27 
underwent CABG with surgical ventricular re-
construction (Table 1 in the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Of the 501 patients who were as-
signed to undergo CABG with surgical ventricu-
lar reconstruction, 454 (91%) underwent the as-
signed procedure; 12 patients did not undergo any 
surgery, and 35 patients underwent CABG with-
out surgical ventricular reconstruction.
Of the 979 patients who underwent surgery, 
the procedure was elective in 819 patients (84%), 
urgent in 127 (13%), performed for ongoing isch-
emia in 21 (2%), and performed under emergency 
conditions in 11 (1%) (Table 2 in the Supplemen-
tary Appendix). Mitral-valve surgery was performed 
in 178 patients (18%) undergoing surgery. More 
arterial conduits were used in patients under-
going CABG alone than in patients undergoing 
CABG with surgical ventricular reconstruction 
(P = 0.008). Surgical ventricular reconstruction add-
ed a median of 27 minutes of cardiopulmonary 
bypass time to the CABG procedure (P<0.001). 
The duration of aortic cross-clamping, the time to 
endotrachael extubation, and the duration of post-
operative hospitalization were longer for patients 
undergoing CABG with surgical ventricular re-
construction (P<0.001 for all comparisons).
Follow-up
The median follow-up for all surviving patients was 
48 months (minimum, 30). Only four patients 
withdrew consent, and six patients were lost to 
follow-up before the last visit. Of the 1000 patients, 
990 (99%) underwent complete follow-up that be-
gan at randomization and concluded between Au-
gust 1 and December 31, 2008.
Left Ventricular Volume
A core-laboratory quantitative assessment of the 
end-systolic volume index on echocardiography was 
performed at baseline and at 4 months in a total 
of 373 patients (212 patients who were assigned to 
undergo CABG alone and 161 who were assigned 
to undergo CABG with surgical ventricular recon-
struction). The mean end-systolic volume index in 
patients assigned to undergo CABG alone de-
creased by an average of 5 ml per square meter, 
from 82 to 77 ml per square meter (a reduction of 
6%). For patients who were assigned to undergo 
CABG with surgical ventricular reconstruction, 
the average decrease was 16 ml per square meter, 
from 83 to 67 ml per square meter (a reduction of 
19%) (Fig. 1 in the Supplementary Appendix). The 
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Table 1. Baseline Characteristics of the Patients.*
Variable
CABG Alone
(N = 499)
CABG with Surgical  
Ventricular Reconstruction
(N = 501)
Demographic characteristics
Age — yr
Median 62 62 
Interquartile range 54–69 55–69
Female sex — no. (%) 78 (16) 69 (14)
Race — no. (%)†
White 451 (90) 460 (92)
Black or other 48 (10) 41 (8)
Body-mass index
Median 27 27
Interquartile range 25–30 24–30
Medical history
Myocardial infarction — no. (%) 435 (87) 437 (87)
Hyperlipidemia — no. (%) 367 (74) 351 (70)
Hypertension — no. (%) 289 (58) 296 (59)
Diabetes — no. (%) 173 (35) 171 (34)
Current smoker — no. (%) 117 (23) 100 (20)
Previous percutaneous coronary intervention — no. (%) 100 (20) 95 (19)
Chronic renal insufficiency — no. (%) 42 (8) 43 (9)
Stroke — no. (%) 28 (6) 28 (6)
Previous CABG  — no. (%) 15 (3) 9 (2)
Current Canadian Cardiovascular Society angina class  
— no. (%)
No angina 121 (24) 128 (26)
I 36 (7) 35 (7)
II 94 (19) 94 (19)
III 203 (41) 205 (41)
IV 45 (9) 39 (8)
Current New York Heart Association heart failure class  
— no. (%)
I 36 (7) 50 (10)
II 222 (44) 207 (41)
III 210 (42) 218 (44)
IV 31 (6) 26 (5)
Blood pressure — mm Hg
Systolic
Median 120 120
Interquartile range 110–130 110–130
Diastolic
Median 71 74
Interquartile range 65–80 66–80
Pulse — beats/min
Median 70 72 
Interquartile range 64–80 64–80
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Table 1. (Continued.)
Variable
CABG Alone
(N = 499)
CABG with Surgical  
Ventricular Reconstruction
(N = 501)
Baseline laboratory measure
Creatinine — mg/dl
Median 1.1 1.1 
Interquartile range 0.9–1.3 0.9–1.3
Left ventricular function
Left ventricular ejection fraction — %
Median 28 28
Interquartile range 23–31 24–31
End-systolic volume index — ml/m2
Median 82 82 
Interquartile range 65–102 66–105
Akinesia or dyskinesia of anterior wall — %
Median 56 50 
Interquartile range 40–60 40–60
Mitral regurgitation — no. (%)‡
None or trace 173 (35) 190 (38)
Mild (≤2+) 233 (47) 216 (43)
Moderate (3+) 72 (14) 70 (14)
Severe (4+) 16 (3) 20 (4)
Not assessed 5 (1) 5 (1)
Coronary anatomy
No. of vessels with stenosis of ≥50% — no. (%)
One 36 (7) 51 (10)
Two 144 (29) 131 (26)
Three 319 (64) 319 (64)
Stenosis of left main coronary artery — no. (%) 
50–74% 72 (14) 61 (12)
≥75% 31 (6) 33 (7)
≥75% Stenosis of proximal left anterior descending  
coronary artery — no. (%)
388 (78) 369 (74)
Duke Coronary Artery Disease Severity Index§
Median — % 65 65
Interquartile range — % 43–91 39–91
Medication at baseline — %
Beta-blocker 85 87
ACE inhibitor or angiotensin-receptor blocker 87 89
ACE inhibitor 80 82
Digoxin 17 14
Diuretic 69 66
Aspirin 77 77
Aspirin or warfarin 81 83
Statin 79 75
* P>0.05 for all between-group comparisons. The body-mass index is the weight in kilograms divided by the square of the 
height in meters. ACE denotes angiotensin-converting enzyme, and CABG coronary-artery bypass grafting. 
† Race was self-reported.
‡ Mitral regurgitation was rated with the use of color Doppler and semiquantitative methods.
§ The Duke Coronary Artery Disease Severity Index ranges from 0 to 100, with higher values indicating greater severity.
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difference between the two groups in the change 
from baseline was significant (P<0.001).
Symptoms
Among patients in both study groups, the propor-
tion with no angina increased and the proportion 
with CCS class III or IV angina decreased during 
the interval from baseline to the last follow-up 
visit (Fig. 2A). The symptoms of patients in both 
study groups improved by an average of 1.7 classes 
(P = 0.84 for the difference between the two groups 
in the change from baseline). Likewise, in the two 
groups, the proportion with New York Heart As-
sociation (NYHA) class I heart failure (no symp-
toms) increased and the proportion with class III 
or IV heart failure decreased during the interval 
from baseline to the last follow-up visit (Fig. 2B). 
The symptoms in the two study groups improved 
by an average of one NYHA class (P = 0.70 for the 
difference between the two groups in the change 
from baseline).
6-Minute Walk Test
In the two study groups, approximately three quar-
ters of patients performed the 6-minute walk test 
at baseline, and a similar proportion did so at 
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Figure 2. Angina and Heart-Failure Symptoms at Baseline and at the Last Follow-up Visit.
Symptoms of angina, classified according to criteria f the Canadian Cardiovascular Society (CCS), and symptoms  
of heart failure, classified according to criteria of the New York Heart Association (NYHA), improved significantly for 
the 499 patients who underwent coronary-artery bypass grafting (CABG) alone and for the 501 patients who under-
went CABG with surgical ventricular reconstruction (SVR) between baseline and the latest follow-up visit, at a median 
of 48 months. Angina symptoms improved by an average of 1.7 classes in both cohorts (P = 0.84) (Panel A). Heart-
failure symptoms improved by an average of one class in both cohorts (P = 0.70) (Panel B).
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4 months (Fig. 2 in the Supplementary Appendix). 
The median distance walked was 350 m at base-
line and 350 m at 4 months for patients assigned 
to undergo CABG and 358 m at baseline and 410 m 
at 4 months for those assigned to undergo CABG 
with surgical ventricular reconstruction. The in-
crease in the median distance walked was simi-
lar in the two groups (48 m among patients who 
were assigned to undergo CABG and 52 m among 
patients assigned to undergo CABG with surgical 
ventricular reconstruction, P = 0.80). Among pa-
tients assigned to undergo CABG who performed 
the 6-minute walk test and were assessed for symp-
toms, 34% were symptomatic during the base-
line test and 9% were symptomatic at 4 months. 
The corresponding rates among patients assigned 
to undergo CABG with surgical ventricular recon-
struction were 33% and 11%.
Primary Outcome
The primary outcome of death from any cause or 
hospitalization for cardiac causes occurred in 292 
of 499 patients (59%) assigned to undergo CABG 
and in 289 of 501 patients (58%) assigned to un-
dergo CABG with surgical ventricular reconstruc-
tion (hazard ratio for the combined approach, 
0.99; 95% confidence interval [CI], 0.84 to 1.17; 
P = 0.90) (Table 2 and Fig. 3A). Fatal events of any 
Table 2. Outcomes and Subsequent Procedures.* 
Variable
CABG Alone
(N = 499)
CABG with Surgical 
Ventricular  
Reconstruction
(N = 501)
Hazard Ratio
(95% CI) P Value
number (percent)
Outcome
Death from any cause or hospitalization for cardiac causes 292 (59) 289 (58) 0.99 (0.84–1.17) 0.90
Death from any cause 141 (28) 138 (28) 1.00 (0.79–1.26) 0.98
Death from any cause within 30 days after randomization  
(intention-to-treat analysis)
22 (4) 30 (6) 0.26
Death from any cause within 30 days after surgery†
Intention-to-treat analysis 25 (5) 26 (5) 0.88
As-treated analysis 23 (5) 28 (6) 0.40
Hospitalization
For any cause 272 (55) 268 (53) 0.98 (0.83–1.16) 0.82
For cardiac causes 211 (42) 204 (41) 0.97 (0.80–1.18) 0.73
Acute myocardial infarction 22 (4) 20 (4) 1.01 (0.54–1.87) 0.96
Stroke 31 (6) 23 (5) 0.77 (0.45–1.32) 0.35
Subsequent procedure‡
CABG 0 1 (<1)
Placement of left ventricular assist device 2 (<1) 2 (<1)
Heart transplantation 2 (<1) 7 (1)
Percutaneous coronary intervention 32 (6) 17 (3)
Placement of pacemaker
For resynchronization 31 (6) 30 (6)
For heart rate 44 (9) 47 (9)
Placement of implantable cardioverter–defibrillator 100 (20) 86 (17)
* Hazard ratios are for coronary-artery bypass grafting (CABG) with surgical ventricular reconstruction as compared with CABG alone. 
† For the analysis of death within 30 days after surgery, in the group that was assigned to undergo CABG alone, 490 patients were evaluated 
in the intention-to-treat analysis and 498 patients in the as-treated analysis; in the group that was assigned to undergo CABG with surgical 
ventricular reconstruction, 489 patients were evaluated in the intention-to-treat analysis and 481 patients in the as-treated analysis.
‡ Hazard ratios and P values are not provided for subsequent procedures because of the low incidence of these events.
The New England Journal of Medicine 
Downloaded from nejm.org on March 26, 2014. For personal use only. No other uses without permission. 
 Copyright © 2009 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 360;17 nejm.org april 23, 20091714
cause occurred in 141 patients (28%) assigned to 
undergo CABG and in 138 patients (28%) assigned 
to undergo CABG with surgical ventricular recon-
struction (hazard ratio, 1.00; 95% CI, 0.79 to 1.26; 
P = 0.98) (Table 2 and Fig. 3B). Hospitalization for 
cardiac causes occurred in 211 patients (42%) and 
in 204 patients (41%), respectively (P = 0.73). Haz-
ard-ratio plots showed no interaction for the pri-
mary outcome between study-group assignment 
and baseline characteristics of interest (Fig. 4).
Secondary Outcomes and Events
Operative rates of death (i.e., deaths occurring 
within 30 days after the procedure) did not differ 
significantly between the two study groups, ac-
cording to either the intention-to-treat analysis or 
the as-treated analysis (Table 2). The rates of seven 
secondary procedures, of acute myocardial infarc-
tion (P = 0.96), and of stroke (P = 0.35) were low and 
similar in the two groups.
Discussion
We compared the efficacy of CABG alone with 
that of CABG combined with surgical ventricular 
reconstruction in patients with coronary artery 
disease and left ventricular systolic dysfunction. 
As anticipated, the addition of surgical ventricu-
lar reconstruction resulted in a significantly great-
er reduction in left ventricular volume than was 
achieved with CABG alone. However, this improve-
ment in ventricular volume did not translate into 
a measurable benefit for the patients. Symptom-
atic improvement after surgery was similar in the 
two study groups. There was no significant be-
tween-group difference in the primary outcome 
of death or hospitalization for cardiac causes or 
in any other clinical outcome. Operative, intuba-
tion, and initial hospitalization times were longer 
in patients treated with the combined procedure. 
The findings of this study do not support the use 
of surgical ventricular reconstruction in the pop-
ulation studied.
Two reasons might be offered for the negative 
outcome of this trial. Perhaps experienced sur-
geons decided to enroll patients for whom they 
recognized that surgical ventricular reconstruction 
would prove unnecessary but offered this proce-
dure directly, instead of enrollment in the trial, to 
all concurrently evaluated patients for whom they 
were confident the procedure would be benefi-
cial. Making such precise decisions about patient 
selection is not consistent with the diverse opin-
ions about the eligibility of specific patients for 
randomized assignment to surgical ventricular re-
construction, as discussed at STICH investigator 
meetings. Participating investigators appeared to 
make randomization decisions from a broad spec-
trum of positions of equipoise on the basis of dif-
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Figure 3. Kaplan–Meier Estimates of Outcomes. 
Panel A shows the probability of the primary outcome (death from any 
cause or hospitalization for cardiac causes), which did not differ signifi-
cantly between the two groups. The primary outcome occurred in 292 pa-
tients (59%) assigned to undergo coronary-artery bypass grafting (CABG) 
alone and in 289 patients (58%) assigned to undergo CABG with surgical 
ventricular reconstruction (SVR) (hazard ratio, 0.99; 95% CI, 0.84 to 1.17). 
Panel B shows the probability of death from any cause, which occurred in 
141 patients (28%) assigned to undergo CABG and in 138 patients (28%) as-
signed to undergo CABG with SVR (hazard ratio, 1.00; 95% CI, 0.79 to 1.26).
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ferences in judgment in weighing baseline clinical 
and imaging characteristics of potential partici-
pants in the trial.
The more plausible reason for the lack of ben-
efit seen with surgical ventricular reconstruction 
is that benefits anticipated from surgical reduction 
of left ventricular volume (reduced wall stress and 
improvement in systolic function) are counter-
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Figure 4. Primary Outcome in Subgroups of Interest. 
Hazard-ratio plots for selected characteristics of patients at baseline show no significant interaction with the study-
group assignment. CABG denotes coronary-artery bypass grafting, CCS Canadian Cardiovascular Society, LAD left 
anterior descending coronary artery, LM left main coronary artery, LVEF left entricular ejection fraction, NYHA 
New York Heart Association, and SVR surgical ventricular reconstruction.
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balanced by a reduction in diastolic distensibility. 
Previous work has shown that an important pre-
dictor of survival in patients with systolic dysfunc-
tion is the left ventricular ejection fraction during 
exercise.23 The most favorable dynamic response 
of the ventricle to the demand for increased car-
diac output is associated with both an increase 
in end-diastolic volume and a decrease in end-
systolic volume. Surgical ventricular reconstruction 
may impede this enhanced filling response.
One limitation of the design of the STICH trial 
was that physicians and surgeons caring for pa-
tients were aware of the treatment received. We 
sought to mitigate this limitation as much as pos-
sible by seeking complete follow-up for all pa-
tients and by selecting trial end points that were 
not primarily subjective ones. It is conceivable that 
the decision to hospitalize a patient during the 
follow-up period could have been influenced by 
the physician’s knowledge of the specific opera-
tion performed. However, rates of death, myo-
cardial infarction, and stroke were similar in the 
two study groups.
A total of 83 of 1000 patients (8%) did not re-
ceive the assigned treatment. Patients who were 
identified before randomization as eligible for ei-
ther treatment could be expected to have a higher 
preoperative crossover rate than patients for whom 
one operative strategy was preferred. Moreover, 
physician-directed crossovers were similar in the 
two study groups. Analyses that were performed 
on the intention-to-treat principle and according 
to the surgery received had similar results.
In summary, our trial compared the efficacy 
of CABG alone with that of CABG with surgical 
ventricular reconstruction in patients with coro-
nary artery disease and left ventricular systolic 
dysfunction. There was no significant difference 
between the two study groups in the degree of 
symptom improvement or in the rate of death or 
hospitalization for cardiac causes.
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